Logo image of SXTP

60 DEGREES PHARMA INC (SXTP) Stock Fundamental Analysis

NASDAQ:SXTP - US83006G4010 - Common Stock

1.42 USD
+0.05 (+3.56%)
Last: 9/9/2025, 5:20:07 PM
1.42 USD
0 (0%)
After Hours: 9/9/2025, 5:20:07 PM
Fundamental Rating

2

Taking everything into account, SXTP scores 2 out of 10 in our fundamental rating. SXTP was compared to 195 industry peers in the Pharmaceuticals industry. SXTP may be in some trouble as it scores bad on both profitability and health. SXTP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SXTP has reported negative net income.
In the past year SXTP has reported a negative cash flow from operations.
SXTP had negative earnings in each of the past 5 years.
In the past 5 years SXTP always reported negative operating cash flow.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

SXTP has a worse Return On Assets (-198.65%) than 89.74% of its industry peers.
SXTP's Return On Equity of -342.13% is on the low side compared to the rest of the industry. SXTP is outperformed by 75.38% of its industry peers.
Industry RankSector Rank
ROA -198.65%
ROE -342.13%
ROIC N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

Looking at the Gross Margin, with a value of 63.74%, SXTP is in the better half of the industry, outperforming 71.28% of the companies in the same industry.
In the last couple of years the Gross Margin of SXTP has declined.
The Profit Margin and Operating Margin are not available for SXTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

3

2. Health

2.1 Basic Checks

SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SXTP has been increased compared to 1 year ago.
The debt/assets ratio for SXTP is higher compared to a year ago.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -18.09, we must say that SXTP is in the distress zone and has some risk of bankruptcy.
SXTP's Altman-Z score of -18.09 is on the low side compared to the rest of the industry. SXTP is outperformed by 79.49% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that SXTP is not too dependend on debt financing.
SXTP has a Debt to Equity ratio (0.06) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -18.09
ROIC/WACCN/A
WACC9.89%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

SXTP has a Current Ratio of 2.27. This indicates that SXTP is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SXTP (2.27) is comparable to the rest of the industry.
SXTP has a Quick Ratio of 1.80. This is a normal value and indicates that SXTP is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of SXTP (1.80) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 1.8
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

SXTP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -512.57%.
Looking at the last year, SXTP shows a very strong growth in Revenue. The Revenue has grown by 120.64%.
Measured over the past years, SXTP shows a very negative growth in Revenue. The Revenue has been decreasing by -52.49% on average per year.
EPS 1Y (TTM)-512.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.09%
Revenue 1Y (TTM)120.64%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%146.3%

3.2 Future

Based on estimates for the next years, SXTP will show a very strong growth in Earnings Per Share. The EPS will grow by 25.73% on average per year.
Based on estimates for the next years, SXTP will show a very strong growth in Revenue. The Revenue will grow by 82.46% on average per year.
EPS Next Y94.26%
EPS Next 2Y38.52%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue Next Year94.66%
Revenue Next 2Y95.15%
Revenue Next 3Y82.46%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SXTP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SXTP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

SXTP's earnings are expected to grow with 25.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.52%
EPS Next 3Y25.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SXTP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

60 DEGREES PHARMA INC

NASDAQ:SXTP (9/9/2025, 5:20:07 PM)

After market: 1.42 0 (0%)

1.42

+0.05 (+3.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/dmh
Earnings (Next)N/A N/A
Inst Owners14.46%
Inst Owner Change-49.28%
Ins Owners1.22%
Ins Owner Change0.44%
Market Cap5.82M
Analysts80
Price Target7.14 (402.82%)
Short Float %2.55%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.98%
Min EPS beat(2)-27.66%
Max EPS beat(2)-16.31%
EPS beat(4)0
Avg EPS beat(4)-80.11%
Min EPS beat(4)-247.17%
Max EPS beat(4)-16.31%
EPS beat(8)1
Avg EPS beat(8)-42.74%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.66%
Min Revenue beat(2)-29.6%
Max Revenue beat(2)0.28%
Revenue beat(4)1
Avg Revenue beat(4)-19.46%
Min Revenue beat(4)-45.31%
Max Revenue beat(4)0.28%
Revenue beat(8)1
Avg Revenue beat(8)-27.25%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)20.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.29%
EPS NY rev (1m)0%
EPS NY rev (3m)42.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.98
P/FCF N/A
P/OCF N/A
P/B 2.4
P/tB 2.55
EV/EBITDA N/A
EPS(TTM)-21.66
EYN/A
EPS(NY)-3.11
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0.24
BVpS0.59
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -198.65%
ROE -342.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.74%
FCFM N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
F-Score3
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 145.9%
Cap/Sales 10.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 1.8
Altman-Z -18.09
F-Score3
WACC9.89%
ROIC/WACCN/A
Cap/Depr(3y)258.14%
Cap/Depr(5y)228.76%
Cap/Sales(3y)28.01%
Cap/Sales(5y)17.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-512.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.09%
EPS Next Y94.26%
EPS Next 2Y38.52%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue 1Y (TTM)120.64%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%146.3%
Revenue Next Year94.66%
Revenue Next 2Y95.15%
Revenue Next 3Y82.46%
Revenue Next 5YN/A
EBIT growth 1Y13.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.33%
OCF growth 3YN/A
OCF growth 5YN/A